Srpski arhiv za celokupno lekarstvo 2011 Volume 139, Issue 11-12, Pages: 824-827
https://doi.org/10.2298/SARH1112824P
Full text ( 182 KB)
The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy
Popović Nataša (Klinika za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Stojković-Švirtlih Neda (Klinika za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Simonović-Babić Jasmina (Klinika za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Boričić Ivan (Institut za patološku anatomiju, Medicinski fakultet, Beograd)
Tomanović Nada (Institut za patološku anatomiju, Medicinski fakultet, Beograd)
Mitrović Nikola (Klinika za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Delić Dragan (Klinika za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Introduction. Reactivation of chronic hepatitis B virus (HBV) infection often
occurs in hepatitis B surface antigen (HBsAg) positive patients undergoing
immunosuppressive or chemotherapy, but can also occur in HBsAg negative,
anti-HB core positive patients. Treatment of HBV reactivation with lamivudin
results in favourable outcome in the majority of patients. The aim of the
authors was to show the effect of lamivudin therapy to HBV reactivation
caused by immunosuppressive therapy. Outline of Cases. The first patient was
a 35-year-old woman with chronic hepatitis B virus infection who underwent
prednisolone therapy for pulmonal sarcoidosis. Four months after the
beginning of the therapy she presented with jaundice and a significant
increase in serum aminotransferase level. Liver biopsy showed chronic viral B
hepatitis of strong activity in the stage of rapidly developed cirrhosis. The
patient was treated with lamivudine with slow reduction of prednisolone
doses, which resulted in full clinical and biochemical recovery. The second
patient was a 40-year-old HBsAg negative female with a previous history of
resolved acute B hepatitis who received chemotherapy for non-Hodgkin
lymphoma. After the third cycle of chemotherapy a significant increase in
aminotransferase level occurred, chemotherapy was discontinued, but
aminotransferase level still increased. At that moment she was found to be
HBsAg positive, and PCR analysis detected a high viral load. Lamivudine
treatment resulted in the patient’s recovery and allowed further
chemotherapy. Conclusion. In case of the reactivation of chronic HBV
infection during immunosuppressive therapy, it should be stopped and
antiviral therapy should be immediately initiated. The use of lamivudine
results in rapid suppression of serum HBV DNA, improves the outcome and
enables the continuation of immunosuppressive and chemotherapy.
Keywords: chronic HBV infection, immunosuppressive therapy, lamivudine